SAHPRA WARNS OF INCREASED BRAIN TUMOUR RISK WITH SPECIFIC CONTRACEPTIVE USE
Sat 18 January 2025: The South African Health Products Regulatory Authority (SAHPRA) has advised that the product information for medroxyprogesterone acetate (MPA) be updated to include revised safety warnings, including the risk of meningioma. MPA is a synthetic oral and injectable form of the hormone progesterone and is used for birth control and the management […]
Continue Reading
